Option program for the CEO and the deputy CEO

Magnus Nilsson (CEO) has bought 400,000 options and Christoffer Rosenblad (deputy CEO and CFO) has bought 100,000 options via an option program issued by three large shareholders in XVIVO Perfusion AB. Each option gives the right to purchase one XVIVO Perfusion share during a two year period.

The options are valued according to Black-Scholes and gives the right to purchase one XVIVO Perfusion share for SEK 124.00 within a two year period. XVIVO Perfusion AB (publ.) is not the contracting party of this transaction since the options are issued by three large shareholders. The Board of Directors are informed of the transaction and welcomes the option program.

March 22, 2018
Magnus Nilsson, CEO
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

The information was submitted for publication, through the agency of the contact person set out above, at 08:30 am CET on March 22, 2018.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com